Editorial 6.2

Margaret Johnson , Sabine Kinloch-de Loës , Christina K Psomas

A review of the safety of favipiravir – a potential treatment in the COVID-19 pandemic?

Victoria Pilkington , Toby Pepperrell , Andrew Hill

Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19

Toby Pepperrell , Victoria Pilkington , Andrew Owen , Junzheng Wang , Andrew Hill

Minimum costs to manufacture new treatments for COVID-19

Andrew Hill , Junzheng Wang , Jacob Levi , Katie Heath , Joseph Fortunak

Phase 3 trials of new antiretrovirals are not representative of the global HIV epidemic

Toby Pepperrell , Andrew Hill , Michelle Moorehouse et al.

‘Informed and empowered’: a mixed-methods study of crowdsourcing contests to promote uptake of HIV self-testing kits among African Americans

Allison Mathews , Donaldson Conserve , Hailey Mason et al.

Willingness to risk death endpoint in HIV cure-related research with otherwise healthy volunteers is misleading

Karine Dubé , Lynda Dee

Highlights of the 9th edition of the Conference on HIV Persistence During Therapy, 10–13 December 2019, Miami, USA

Christina K Psomas , Karl Salzwedell , Mario Stevenson et al.

Summary of the coronavirus disease 2019 (COVID-19) update from the 2020 Conference on Retroviruses and Opportunistic Infections, 8–11 March 2020, Boston, USA

Christina K Psomas , Sabine Kinloch

---